CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The ENRICH trial results were accepted as a late-breaker and will be presented on Saturday, April 22 during an oral plenary session beginning at 8:30 a.m. PT (11:30 a.m. ET) by co-lead ENRICH investigator, Gustavo Pradilla, M.D., associate professor of neurosurgery at Emory University School of Medicine and chief of neurosurgery at Grady Memorial Hospital. 

The researchers found that as hair ages, sheds, and then repeatedly grows back, increasing numbers of McSCs get stuck in the stem cell compartment called the hair follicle bulge. There, they remain, do not mature into the transit-amplifying state, and do not travel back to their original location in the germ compartment, where WNT proteins would have prodded them to regenerate into pigment cells.

Data shows the achievement of the primary endpoint of decreasing esophageal intraepithelial eosinophil count and the positive impact on an array of histological measures of EoE. Favorable safety and tolerability profile consistent with Phase 1 trial results.

Exai Bio notes the findings demonstrate highly sensitive and specific detection of the earliest and smallest tumors using Exai’s novel RNA- and AI-based liquid biopsy platform.

Life Spine notes: The paper assessed the results of 100 patients who underwent transforaminal lumbar spinal fusion via minimally invasive surgery at L4-L5 or L5-S1. The objective of the paper was to see how the ProLift® Expandable Spacer System affected patient reported outcomes, sagittal alignment, and restoration of disc height and foraminal height comparative to static interbody cages.